PRPH
ProPhase Labs Inc.
Company Overview
| Mkt Cap | $12.05M | Price | $0.16 |
| Volume | 187.18K | Change | -5.09% |
| P/E Ratio | -0.2 | Open | $0.17 |
| Revenue | $6.8M | Prev Close | $0.17 |
| Net Income | $-53.4M | 52W Range | $0.08 - $1.15 |
| Div Yield | N/A | Target | $11.00 |
| Overall | 39 | Value | -- |
| Quality | 39 | Technical | -- |
No chart data available
About ProPhase Labs Inc.
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Latest News
ProPhase Labs Secures Flexible $10 Million Equity Facility
ProPhase Labs Announces Uplisting to OTCID Market
ProPhase Labs Updates Shareholders Amid Volatility and OTC Move
ProPhase Labs Announces Immediate Resignation of Board Member
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRPH | $0.16 | -5.1% | 187.18K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |